NR ACEB
AU Calvo,P.; Gouritin,B.; Brigger,I.; Lasmezas,C.I.; Deslys,J.P.; Williams,A.; Andreux,J.P.; Dormont,D.; Couvreur,P.
TI PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases
QU Journal of Neuroscience Methods 2001 Oct 30; 111(2): 151-5
PT journal article
AB PEGylated polymeric nanoparticles are hereby presented as a potential efficient drug carrier for the delivery of active therapeutic molecules in prion experimental diseases. Based on their blood long-circulating characteristics, these PEGylated particles made by the amphiphilic copolymer poly [methoxy poly(ethylene glycol) cyanoacrylate-co-hexadecyl cyanoacrylate] (PEG-PHDCA), showed comparatively conventional non-PEGylated nanoparticles, a higher uptake by the spleen and the brain which are both the target tissues of PrPres accumulation in scrapie infected animals.
MH Animal; *Biocompatible Materials/pharmacokinetics; Blood/metabolism; Brain/metabolism; Comparative Study; *Cyanoacrylates/pharmacokinetics; Drug Carriers; Injections, Intravenous; Male; Osmolar Concentration; Particle Size; *Polyethylene Glycols/pharmacokinetics; Rats; Scrapie/*drug therapy/physiopathology; Support, Non-U.S. Gov't; Tissue Distribution
AD UMR CNRS 8612, Physico-Chimie-Pharmacotechnie-Biopharmacie, Faculte de Pharmacie, Universite Paris-Sud XI, 5, rue Jean Baptiste Clement, 92296, Chatenay-Malabry, France.
SP englisch
PO Niederlande